SCHEMBL5994753

SCHEMBL5994753

CCn1c(SCc2ccc(C(F)(F)F)cc2)nnc1-c1ccc(N(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.54
▸ TSHR P16473 5/20 0.54
▸ HDAC2 Q92769 2/20 0.52
▸ KMT2A Q03164 7/20 0.50
▸ MEN1 O00255 6/20 0.50
▸ CYP1A2 P05177 5/20 0.50
▸ CYP2C19 P33261 5/20 0.50
▸ ATM Q13315 1/20 0.49
▸ ALDH1A1 P00352 7/20 0.48
▸ CYP2C9 P11712 5/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ LMNA P02545 6/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ GPBAR1 Q8TDU6 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ HTT P42858 5/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.46
▸ RECQL P46063 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209345 0.86 HDAC2 (0.56) CYP3A4TSHRHDAC2KMT2AMEN1
SCHEMBL4212550 0.84 CYP3A4 (0.76) CYP3A4TSHRHDAC2KMT2AMEN1
SCHEMBL4214098 0.84 CYP3A4 (0.54) CYP3A4TSHRHDAC2KMT2AMEN1
SCHEMBL4199189 0.83 CYP3A4 (0.73) CYP3A4TSHRHDAC2KMT2AMEN1
SCHEMBL4215625 0.81 ALDH1A1 (0.57) CYP3A4TSHRHDAC2KMT2AMEN1
SCHEMBL4211607 0.79 ALDH1A1 (0.76) CYP3A4TSHRHDAC2KMT2AMEN1
SCHEMBL4206360 0.79 HDAC2 (0.58) CYP3A4TSHRHDAC2KMT2AMEN1
SCHEMBL5995926 0.78 CYP3A4 (0.59) CYP3A4TSHRKMT2AMEN1CYP1A2
SCHEMBL4203822 0.77 TSHR (0.76) CYP3A4TSHRKMT2AMEN1CYP1A2
SCHEMBL4209470 0.77 LMNA (0.56) CYP3A4TSHRHDAC2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100235-A1 Pharmaceutical use of substituted 1,2,4-triazoles NOVO NORDISK A/S (DK) 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100235-A1 Pharmaceutical use of substituted 1,2,4-triazoles HSD3B1, HSD11B1, HSD3B2 CYP3A4 48/4885TSHR 2592/4885HDAC2 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback